UNSPSC 51183502: Buformin

This classification denotes an anti-diabetic agent with the molecular formula C6H15N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W2115E9C7B, chemically known as imidodicarbonimidic diamide, n-butyl- but more generally known as buformin, which bears US NIH Compound Identifier 2468. Buformin most often comes in base and hydrochloride forms. European Medicines Agency schedules Buformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05965MIG.

UNSPSC 51183502 Buformin, a Commodity code, covers procurement of the antidiabetic medication buformin — a biguanide oral agent used to treat type 2 diabetes — by state and local health departments, correctional facilities, and public health agencies. State and local governments purchase buformin primarily through formulary procurement for inmate and patient populations in correctional institutions, public hospitals, and state health clinics, often bundled with broader pharmaceutical supply contracts or managed through state Medicaid programs and group purchasing agreements. The medication is typically solicited as part of standing pharmaceutical supply contracts rather than as a discrete line-item purchase.

The source provided contains no recent state and local contract opportunities tagged to this code, so current market activity cannot be characterized. Without access to recent RFP, RFQ, IFB, or ITB records, the geographic concentration, issuing-body profile, and representative opportunity examples cannot be determined. Firms pursuing buformin procurement should monitor state health department, corrections department, and Medicaid managed-care organization RFPs, as well as cooperative purchasing vehicle updates through entities such as NASCIO, NASPO ValuePoint, and regional public-sector group purchasing organizations, which typically consolidate pharmaceutical contracts across multiple jurisdictions.